Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Q2 Earnings Roundup: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Segment

By: StockStory

August 19, 2025 at 23:34 PM EDT

VTRS Cover Image

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q2, starting with Viatris (NASDAQ: VTRS).

The generic pharmaceutical industry operates on a volume-driven, low-cost business model, producing bioequivalent versions of branded drugs once their patents expire. These companies benefit from consistent demand for affordable medications, as they are critical to reducing healthcare costs. Generics typically face lower R&D expenses and shorter regulatory approval timelines compared to branded drug makers, enabling cost efficiencies. However, the industry is highly competitive, with intense pricing pressures, thin margins, and frequent legal challenges from branded pharmaceutical companies over patent disputes. Looking ahead, the industry is supported by tailwinds such as the role of AI in streamlining drug development (reverse engineering complex formulations) and manufacturing efficiency (optimize processes and remove inefficiencies). Governments and insurers' focus on reducing drug costs can also boost generics' adoption. However, headwinds include escalating pricing pressure from large buyers like pharmacy chains and healthcare distributors as well as evolving regulatory hurdles.

The 4 generic pharmaceuticals stocks we track reported a strong Q2. As a group, revenues beat analysts’ consensus estimates by 2.8%.

Luckily, generic pharmaceuticals stocks have performed well with share prices up 26.9% on average since the latest earnings results.

Viatris (NASDAQ: VTRS)

Created through the 2020 merger of Mylan and Pfizer's Upjohn division, Viatris (NASDAQ: VTRS) is a healthcare company that develops, manufactures, and distributes branded and generic medicines across more than 165 countries worldwide.

Viatris reported revenues of $3.58 billion, down 5.6% year on year. This print exceeded analysts’ expectations by 4.2%. Overall, it was a strong quarter for the company with a beat of analysts’ EPS estimates and a narrow beat of analysts’ full-year EPS guidance estimates.

Viatris delivered the slowest revenue growth and weakest full-year guidance update of the whole group. Interestingly, the stock is up 22.6% since reporting and currently trades at $10.71.

Is now the time to buy Viatris? Access our full analysis of the earnings results here, it’s free.

Best Q2: ANI Pharmaceuticals (NASDAQ: ANIP)

With a diverse portfolio of 116 pharmaceutical products and a growing rare disease platform, ANI Pharmaceuticals (NASDAQ: ANIP) develops, manufactures, and markets branded and generic prescription pharmaceuticals, with a focus on rare disease treatments.

ANI Pharmaceuticals reported revenues of $211.4 million, up 53.1% year on year, outperforming analysts’ expectations by 10.4%. The business had a stunning quarter with a beat of analysts’ EPS estimates and an impressive beat of analysts’ full-year EPS guidance estimates.

ANI Pharmaceuticals delivered the biggest analyst estimates beat, fastest revenue growth, and highest full-year guidance raise among its peers. The market seems happy with the results as the stock is up 30.3% since reporting. It currently trades at $89.80.

Is now the time to buy ANI Pharmaceuticals? Access our full analysis of the earnings results here, it’s free.

Amphastar Pharmaceuticals (NASDAQ: AMPH)

Founded in 1996 and known for its expertise in complex drug formulations, Amphastar Pharmaceuticals (NASDAQ: AMPH) develops and manufactures technically challenging injectable and inhalation medications, including both generic and proprietary pharmaceutical products.

Amphastar Pharmaceuticals reported revenues of $174.4 million, down 4.4% year on year, falling short of analysts’ expectations by 1%. It was a mixed quarter as it posted a beat of analysts’ EPS estimates.

Interestingly, the stock is up 40% since the results and currently trades at $30.32.

Read our full analysis of Amphastar Pharmaceuticals’s results here.

Amneal (NASDAQ: AMRX)

Founded in 2002 and growing into one of America's largest generic drug producers, Amneal Pharmaceuticals (NASDAQ: AMRX) develops, manufactures, and distributes generic medicines, specialty branded drugs, biosimilars, and injectable products for the U.S. healthcare market.

Amneal reported revenues of $724.5 million, up 3.2% year on year. This result missed analysts’ expectations by 2.5%. All in all, it was a mixed quarter for the company.

Amneal had the weakest performance against analyst estimates among its peers. The stock is up 14.8% since reporting and currently trades at $9.16.

Read our full, actionable report on Amneal here, it’s free.

Market Update

In response to the Fed’s rate hikes in 2022 and 2023, inflation has been gradually trending down from its post-pandemic peak, trending closer to the Fed’s 2% target. Despite higher borrowing costs, the economy has avoided flashing recessionary signals. This is the much-desired soft landing that many investors hoped for. The recent rate cuts (0.5% in September and 0.25% in November 2024) have bolstered the stock market, making 2024 a strong year for equities. Donald Trump’s presidential win in November sparked additional market gains, sending indices to record highs in the days following his victory. However, debates continue over possible tariffs and corporate tax adjustments, raising questions about economic stability in 2025.

Want to invest in winners with rock-solid fundamentals? Check out our Top 6 Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.

About Us

Laser Focus World Membership

Magazine Subscription

Newsletter Subscription

The Daily Beam

Product Watch

Bio & Life Sciences Product Watch

Laser Processing Product Watch

Get Published!

Photonics Hot List

Following the Photons: A Photonics Podcast

Social Media

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board